Nuveen
ORIC icon

Nuveen’s Oric Pharmaceuticals ORIC Stock Holding History

Nuveen’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86M Buy
172,167
+19,145
+13% +$174K ﹤0.01% 2605
2026
Q1 		$1.94M Buy
153,022
+8,619
+6% +$97.8K ﹤0.01% 2292
2025
Q4 		$1.18M Buy
144,403
+6,711
+5% +$77.3K ﹤0.01% 2544
2025
Q3 		$1.65M Buy
137,692
+15,006
+12% +$158K ﹤0.01% 2376
2025
Q2 		$1.25M Sell
122,686
-44,816
-27% -$301K ﹤0.01% 2510
2025
Q1 		$935K Hold
167,502
– – ﹤0.01% 2668
2024
Q4 		$1.35M Hold
167,502
– – ﹤0.01% 2560
2024
Q3 		$1.72M Buy
167,502
+1,309
+0.8% +$12.9K ﹤0.01% 2492
2024
Q2 		$1.17M Buy
166,193
+30,406
+22% +$272K ﹤0.01% 2653
2024
Q1 		$1.87M Hold
135,787
– – ﹤0.01% 2437
2023
Q4 		$1.25M Sell
135,787
-33,232
-20% -$240K ﹤0.01% 2627
2023
Q3 		$1.02M Hold
169,019
– – ﹤0.01% 2562
2023
Q2 		$1.31M Buy
+169,019
New +$960K ﹤0.01% 2534
2022
Q2 		– Sell
-112,748
Closed -$753K – 3423
2022
Q1 		$753K Buy
112,748
+1,589
+1% +$14.3K ﹤0.01% 2905
2021
Q4 		$1.31M Sell
111,159
-8,058
-7% -$126K ﹤0.01% 2754
2021
Q3 		$3.01M Buy
119,217
+4,019
+3% +$81.5K ﹤0.01% 2483
2021
Q2 		$2.04M Buy
115,198
+42,000
+57% +$920K ﹤0.01% 2704
2021
Q1 		$1.79M Buy
73,198
+5,202
+8% +$164K ﹤0.01% 2667
2020
Q4 		$2.3M Buy
67,996
+34,152
+101% +$980K ﹤0.01% 2436
2020
Q3 		$846K Buy
33,844
+151
+0.4% +$3.59K ﹤0.01% 2754
2020
Q2 		$1.14M Buy
+33,693
New +$1.08M ﹤0.01% 2573

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nuveen's ORIC Position: Q2 2026 in Review

Nuveen increased its Oric Pharmaceuticals (ORIC) stake by 13% in Q2 2026, buying an estimated $174K and bringing the position to 172,167 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #2605.

Nuveen first reported a position in ORIC in Q2 2020 and has held it in 21 quarters since. The position peaked at $3.01M in Q3 2021. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Nuveen held 172,167 shares of Oric Pharmaceuticals worth $1.86M as of Q2 2026.
  • Nuveen bought 19,145 Oric Pharmaceuticals shares in Q2 2026, an estimated $174K.
  • Oric Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2605 holding.
  • Nuveen first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
  • Nuveen's Oric Pharmaceuticals position peaked at $3.01M in Q3 2021.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.